Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs
| Autor: | Neşe Saltoğlu, Harika Öykü Dinç, İlker İnanç Balkan, Günay Can, Doğukan Özbey, Ayşe Nur Beytur, Elif Keskin, Beyhan Budak, Okan Aydoğan, Bilgül Mete, Rıdvan Karaali, Sevgi Ergin, Bekir Kocazeybek |
|---|---|
| Přispěvatelé: | DİNÇ, HARİKA ÖYKÜ |
| Rok vydání: | 2022 |
| Předmět: |
Microbiology (medical)
Vaccines Synthetic COVID-19 Vaccines SARS-CoV-2 Vaccination COVID-19 General Medicine Antibodies Viral Infectious Diseases Antibody Formation SALTOĞLU N. DİNÇ H. Ö. BALKAN İ. İ. CAN G. Ozbey D. BEYTUR A. N. KESKİN E. BUDAK B. Aydogan O. METE B. et al. -Heterologous booster COVID-19 vaccination elicited potent immune responses in HCWs- DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE cilt.104 sa.2 2022 Humans BNT162b2 CoronaVac mRNA Vaccines Vaccine Antibody BNT162 Vaccine |
| Popis: | The objective of our study was to evaluate the antibody responses of health care workers (HCWs) who were vaccinated with booster dose BNT162b2 6 months after 2 doses of the CoronoVac vaccine. The study included 318 HCWs vaccinated with inactive CoronaVac SARS-CoV-2 vaccine in 2 doses. Anti-spike/RBD IgG levels were measured immediately before and 1 month after the booster dose. In the sixth month after CoronaVac vaccination, the median of antibody levels of 1212.02 AU/ML, while it was 9283 AU/mL after BNT162b2 vaccination. IgG antibody titers of over 1050 AU/mL (which is equivalent to 1:80 dilution in the plaque reduction neutralization test) were detected in HCWs 15.09% and 97.8%, respectively. Our results showed that antibody titers increased 8-fold after the booster dose. We believe that the administration of the mRNA vaccine as a booster dose can provide more effective protection against COVID-19 infection, especially in individuals with risk factors. IU-Cerrahpaşa Scientific Research Projects Unit |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|